• LAST PRICE
    19.5700
  • TODAY'S CHANGE (%)
    Trending Up0.0700 (0.3590%)
  • Bid / Lots
    19.5600/ 1
  • Ask / Lots
    19.5800/ 3
  • Open / Previous Close
    19.5300 / 19.5000
  • Day Range
    Low 19.3000
    High 19.8800
  • 52 Week Range
    Low 15.5000
    High 23.4000
  • Volume
    321,394
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 19.5
TimeVolumeEXEL
09:32 ET12106619.795
09:34 ET788319.66
09:36 ET621419.475
09:38 ET1344919.34
09:39 ET1098219.3322
09:41 ET218919.47
09:43 ET3751119.61
09:45 ET2467719.69
09:48 ET1460519.54
09:50 ET996519.55
09:52 ET1313919.59
09:54 ET1397919.57
09:56 ET682519.6
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEXEL
Exelixis Inc
6.3B
23.2x
---
United StatesEXAS
Exact Sciences Corp
8.0B
-10.8x
---
United StatesMRVI
Maravai LifeSciences Holdings Inc
6.7B
14.0x
---
United StatesMEDP
Medpace Holdings Inc
5.5B
31.0x
+67.16%
United StatesIONS
Ionis Pharmaceuticals Inc
6.5B
-234.4x
---
United StatesCRSP
CRISPR Therapeutics AG
6.2B
-9.9x
---
As of 2022-08-11

Company Information

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Contact Information

Headquarters
1851 Harbor Bay ParkwayALAMEDA, CA, United States 94502
Phone
650-837-7000
Fax
650-837-8300

Executives

Independent Chairman of the Board, Co-Founder
Stelios Papadopoulos
President, Chief Executive Officer, Director
Michael Morrissey
Chief Financial Officer, Executive Vice President
Christopher Senner
Executive Vice President - Scientific Strategy, Chief Scientific Officer
Peter Lamb
Executive Vice President, General Counsel, Secretary
Jeffrey Hessekiel

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.3B
Revenue (TTM)
$1.6B
Shares Outstanding
320.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.60
EPS
$0.84
Book Value
$6.93
P/E Ratio
23.2x
Price/Sales (TTM)
4.0
Price/Cash Flow (TTM)
21.7x
Operating Margin
21.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.